Definition, classification and symptoms. The current disease classification is distinguished from the 1864 descriptive label.
Malignant Neoplasms: cell morphology, prominent nucleoli, mitoses and epithelial versus mesenchymal classification.
1856; pp. 35–37 describe fibres, elongated nuclei and fibroplastic cells and discuss recurrence or malignant behaviour. Publication and author verified against wellcomecollection.org/works/wmmt58cd. The historical category is not treated as a unique present diagnosis.
Current patient information headed Breast Cancer Recurrence: local, regional and distant return, and factors affecting recurrence risk.
Pages 548–549; contemporary discussion of caustics, chemical injection and purported prevention of recurrence. Cited as evidence of what was proposed, not as support for those treatments.
Thomas Weeden Cooke, pp. 131–135, nonoperative case records. Period observations of palliation or altered symptoms are not evidence of eradication of cancer.
NG101; pretreatment assessment, surgery, systemic therapy planning and adjuvant treatment.
Imaging, core needle biopsy, pathology, biomarkers and staging.
Lumps, nipple and skin changes, pain and signs of distant disease.
How leukemia starts; Features and symptoms, acute versus chronic disease.
What is leukemia?; Symptoms; Diagnosis. Official National Library of Medicine overview.
Introduction; Classification; Findings at Diagnosis table; Leukemoid reaction. Review February 2026.
Sections on types of cancer, including carcinoma, sarcoma, leukaemia, lymphoma and melanoma.
Cited passages: Donehower and colleagues, 1992, abstract and spontaneous-tumour observations.
Cited passages: Druker and colleagues, 1996, abstract and BCR-ABL-positive versus negative cellular experiments.
Megan I. Brasher and coauthors.
Makoto Horiuchi and coauthors.
Cited material: Mosaic Nrf2 deletion, unstressed controls and 4NQO exposure.
Cited material: Mouse lineage tracing with irradiation and antioxidant intervention.
Iwo Kucinski and coauthors.
Cited material: Figures 5–7; antioxidant response, redox measurements and mosaic CncC activation.
Proceedings of the National Academy of Sciences 109, 15101–15108 (2012). doi.org/10.1073/pnas.1213353109
Relevant passages: pp. 475–480, promoter insertion and cellular oncogene activation.
Relevant passages: pp. 1311–1315, identification of phosphotyrosine in kinase products.
Relevant passages: pp. 1211–1213, RNA-dependent DNA synthesis in virion preparations.
Relevant passages: pp. 397–411, transmission with material separated from tumour cells.
Richard A. Morgan and coauthors. 2010. Molecular Therapy 18, 843–851.
Jesse M. Zaretsky and coauthors. 2016. New England Journal of Medicine 375, 819–829.
Sanjeev Mariathasan and coauthors. 2018. Nature 554, 544–548.
Maartje W. Rohaan and coauthors. 2022. New England Journal of Medicine 387, 2113–2125.
Kari R. Fischer and coauthors. 2015. Nature 527, 472–476.
Ievgenia Pastushenko and coauthors. 2018. Nature 556, 463–468.
Jeff H. Tsai and coauthors. 2012. Cancer Cell 22, 725–736.
Jing Yang and coauthors. 2004. Cell 117, 927–939.
Anirudh Prahallad and coauthors. 2012. Nature 483, 100–103.
Iñigo Martincorena and coauthors. 2017. Cell 171, 1029–1041.e21.
Michael S. Lawrence and coauthors. 2013. Nature 499, 214–218.
Francisco Sanchez-Vega and coauthors. 2018. Cell 173, 321–337.e10.
Berna C. Özdemir and coauthors. 2014. Cancer Cell 25, 719–734.
Cristovão M. Sousa and coauthors. 2016. Nature 536, 479–483.
Published erratum: doi.org/10.1038/nature19851. Consult the corrected article.
Ayuko Hoshino and coauthors. 2015. Nature 527, 329–335.
Jeffrey Wyckoff and coauthors. 2004. Cancer Research 64, 7022–7029.
Akira Orimo and coauthors. 2005. Cell 121, 335–348.
Cited material: Organoid invasion, basal-marker leader cells, and K14/p63 knockdown.
Primary article by Judah Folkman, New England Journal of Medicine 285, 1182–1186, November 18, 1971; DOI 10.1056/NEJM197111182852108. Publisher preview identifies the author and Department of Surgery, Children’s Hospital Medical Center and Harvard Medical School. The article frames tumor cells and capillary endothelial cells as interacting populations and proposes therapeutic implications of angiogenesis dependence.
Original byline: Judah Folkman, Ezio Merler, Charles Abernathy and Gretchen Williams. Journal of Experimental Medicine 133(2), 275–288 (1971), DOI 10.1084/jem.133.2.275; PMID 4332371. Printed p. 275 describes new-vessel outgrowth near membrane chambers containing tumor cells in rat dorsal air sacs, motivating a diffusible-factor interpretation; the abstract reports an angiogenic tumor-derived fraction. Publisher PDF: rupress.org/jem/article-pdf/133/2/275/1084025/275.pdf . The historical fraction is not equated with a single modern chemically defined growth factor.
Additional verified locator: printed p. 279, Biological Assay of TAF and Reading the Air Sac Assay; Figures 1–4. The modified rat dorsal air sac assay used a membrane wick over holes in silicone tubing to deliver tumour fractions, read after 48 hours under a stereoscope at 20×, followed by histological sections. Vascular proliferation was graded 0–5+. Figure 2 shows a negative wick control; Figures 3–4 show positive responses. This biological activity scale is not an absolute endothelial cell count. Primary full-text indexed view: pmc.ncbi.nlm.nih.gov/articles/PMC2138906/ .
Pamela M. Pollock and colleagues, Nature Genetics 33(1), 19–20, January 2003; first online 25 November 2002. DOI 10.1038/ng1054. Abstract: mutation analysis of microdissected samples found the substitution labeled V599E in the original paper in 63 of 77 nevi; the authors distinguish an initiating pathway alteration from sufficient evidence for melanoma tumorigenesis.

Articles by others on the same topic (0)

There are currently no matching articles.